Go Pro
OTCMKTS:MCUJF

Medicure Q4 2025 Earnings Report

Medicure logo
$1.91 0.00 (-0.03%)
As of 10:43 AM Eastern

Medicure EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$6.13 million
Expected Revenue
$3.62 million
Beat/Miss
Beat by +$2.51 million
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Earnings Headlines

Elon gets it. Do you?
Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.tc pixel
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Winnipeg, Manitoba-based specialty pharmaceutical company focused on developing, commercializing and distributing therapies for cardiovascular and related medical conditions. The company serves healthcare markets primarily in North America through its operating subsidiaries and commercial partners.

Medicure’s product portfolio includes AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the treatment of certain patients with acute coronary syndrome and during percutaneous coronary intervention. The company also markets ZYPITAMAG (pitavastatin), an oral statin used to help manage elevated cholesterol levels.

Medicure has historically concentrated on specialty cardiovascular products and has sought to expand its presence through product development, licensing and commercialization activities. The company is led by Dr. Albert D. Friesen, who serves as president and chief executive officer.

View Medicure Profile